Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Jan 2, 2026, 12:53José Antonio García Erce: The National Transplant Organization Published the 2024 Report of the Global Observatory on Donation and Transplantation
-
Jan 2, 2026, 12:48Reza Shojaei: Stepping into 2026 – Your Daily Commitment Saves Lives
-
Jan 2, 2026, 09:36Shashank K R on The Use of Lumbrokinase from Eudrilus eugeniae
-
Jan 2, 2026, 09:20Rehan Khan Explores Clopidogrel
-
Jan 2, 2026, 09:06Gokhan Ozdemir on Thrombophilia in Young Ischemic Stroke
-
Jan 2, 2026, 08:47Raza Ur Rehman on Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B
-
Jan 2, 2026, 03:52Abdul Mannan: When Gender Bias Becomes a Diagnostic Error – Inherited Bleeding Disorders are Still Being Missed
-
Jan 2, 2026, 03:51Samwel Mikaye: Thrombocytopenia in Pregnancy
-
Jan 2, 2026, 03:50Marc Carrier: Clinicians Working With Cancer Patients on DOACs. We Need Your Expertise!